Vineet Laboratories (NSE:VINEETLAB) EBIT: ₹-62.9 Mil (TTM As of Dec. 2025)


NSE:VINEETLAB Vineet Laboratories Ltd NSE:VINEETLAB
38 GF Score
Price ₹34.00
GF Value ₹15.42
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Vineet Laboratories EBIT?

Vineet Laboratories NSE:VINEETLAB +0.18% 38 EBIT is ₹-62.9 Mil as of Dec. 2025. GuruFocus rates NSE:VINEETLAB with a GF Score™ of 38/100 and a GF Value™ of ₹15.42 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Vineet Laboratories's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2025 was ₹19.1 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was ₹-62.9 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Vineet Laboratories's annualized ROC % for the quarter that ended in Dec. 2025 was 11.41%. Vineet Laboratories's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 13.49%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Vineet Laboratories's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -5.87%.


Vineet Laboratories  (NSE:VINEETLAB) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Vineet Laboratories's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

ROC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2025 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=74.6 * ( 1 - 0% )/( (653.712 + 0)/ 1 )
=74.6/653.712
=11.41 %

where

Note: The Operating Income data used here is four times the quarterly (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

Vineet Laboratories's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2025  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=76.504/( ( (242.08 + max(324.885, 0)) + (0 + max(0, 0)) )/ 1 )
=76.504/( ( 566.965 + 0 )/ 1 )
=76.504/566.965
=13.49 %

where Working Capital is:

Working Capital(Q: Sep. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(43.309 + 566.815 + 30.666) - (284.442 + 0 + 31.463)
=324.885

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0) - (0 + 0 + 0)
=0

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Vineet Laboratories's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2025 )
=-62.864/1071.016
=-5.87 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Vineet Laboratories EBIT Related Terms


Vineet Laboratories EBIT Historical Data

* Premium members only.

The historical data trend for Vineet Laboratories's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vineet Laboratories EBIT Chart

Vineet Laboratories Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
EBIT
Get a 7-Day Free Trial Premium Member Only 61.14 108.34 46.88 42.13 -169.45

Vineet Laboratories Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -47.23 -104.68 -2.89 25.59 19.13

NSE:VINEETLAB vs DOW: EBIT Comparison

For the Chemicals subindustry, Vineet Laboratories's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vineet Laboratories EV-to-EBIT vs Chemicals Industry

For the Chemicals industry and Basic Materials sector, Vineet Laboratories's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Vineet Laboratories's EV-to-EBIT falls into.


NSE:VINEETLAB
38GF Score
Vineet Laboratories Ltd NSE:VINEETLAB
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vineet Laboratories EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹-62.9 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of ₹-62.9 Mil mean?
Vineet Laboratories (NSE:VINEETLAB) has a EBIT of ₹-62.9 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Vineet Laboratories.
Is Vineet Laboratories' EBIT too high?
Vineet Laboratories' current EBIT is ₹-62.9 Mil. Overall, Vineet Laboratories has a GF Score™ of 38/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Vineet Laboratories' EBIT compare to DOW?
Vineet Laboratories' EBIT of ₹-62.9 Mil can be compared against companies in the Chemicals industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Chemicals company?
A good EBIT depends on the Chemicals industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Vineet Laboratories. Vineet Laboratories's current EBIT is ₹-62.9 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vineet Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Vineet Laboratories (NSE:VINEETLAB) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹15.42, compared to a current price of ₹34.00 — trading 120.5% above its estimated fair value. The current EBIT is ₹-62.9 Mil. Vineet Laboratories' overall GF Score™ is 38/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Vineet Laboratories (NSE:VINEETLAB), the current EBIT is ₹-62.9 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Vineet Laboratories (NSE:VINEETLAB) Overvalued in 2026?

Based on GuruFocus' analysis, Vineet Laboratories stock appears to be overvalued. The current stock price of ₹34.00 is trading 120.5% above its estimated GF Value™ of ₹15.42. GuruFocus considers Vineet Laboratories to be Significantly Overvalued.

Key valuation signals for NSE:VINEETLAB:

  • EBIT: ₹-62.9 Mil
  • GF Value™: ₹15.42 vs. price of ₹34.00 (120.5% above fair value)
  • GF Score™: 38/100 with 6 warning signs

No single metric tells the full story. See the NSE:VINEETLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Vineet Laboratories Business Description

Other Exchanges 543298:India
Address 5-5-160, Malleswari Nilayam, Chintalakunta, Opposite Vishnu Theatre, L.B Nagar, Hyderabad, TG, IND, 500074
Vineet Laboratories Ltd is engaged in the business of Pharmaceutical intermediates and Fine chemicals. The products of the companies include Dimethyl phenoxy acetyl chloride, Dimethyl Phenoxy Acetic Acid, Nitrophenyl phosphate disodium salt, and others. Geographically, the company operates within India and outside India, with a majority of revenue coming from India. The company has one business segment, the manufacture of Drug Intermediates & Bulk Dugs.
38GF Score

Get the complete analysis for NSE:VINEETLAB

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹34.00
Price
₹15.42
GF Value